New Medications Offer Hope in Tackling America's Obesity Crisis, But Challenges Remain

By IndraStra Global Editorial Team

Obesity has emerged as a significant problem in America, with new medications now offering potential solutions. Despite numerous unanswered questions, these drugs could transform the way obesity is treated. Data from the National Institutes of Health reveals that over 40% of American adults are obese, with nearly 10% classified as severely obese. This condition exacerbates the risk of heart disease, lung disease, cancer, and diabetes, making it the most critical health issue in the country and a key factor in COVID-19 mortality.
Understanding the causes of obesity involves more than just the balance of calories consumed and burned. While eating more calories than burned does lead to weight gain, the process is influenced by various factors such as genes, hormones, metabolism, and gut bacteria. Additionally, lifestyle factors like larger portions in restaurants, pervasive food advertising, and sedentary habits contribute to the rise in obesity. Traditional treatments over the past century, including low-calorie diets, increased physical activity, and counseling, often yielded temporary success, with many patients regaining weight. Surgical options, although effective and relatively safe, are invasive and irreversible, highlighting the persistent demand for pharmacological treatments for obesity.
Several new medications have been introduced in the past decade, including six approved by the U.S. Food and Drug Administration. These newer drugs stimulate hormones that trigger insulin release and readjust fat storage. Semaglutide, marketed as Ozempic and Wegovy, is currently the most popular synthetic mimic of glucagonlike peptide 1 or GLP-1 with a burlier structure that doesn't break down easily and lasts for longer in the body. It is a once-weekly self-administered injection, with slight dosage differences between the brands. Wegovy is designed specifically for weight loss, while Ozempic was initially a diabetes medication promoting weight loss. The latest FDA-approved weight loss drug, tirzepatide, is also an injectable with a slightly different mechanism of action.
Research has consistently shown that these drugs are highly effective for weight loss. Beyond their hormonal effects, they suppress appetite and slow food absorption. Individuals taking these medications for a year typically reduce their caloric intake and lose about 15% of their body weight. Reports indicate that patients also decrease their consumption of sugary carbonated drinks and alcohol. Additionally, a recent study published in the New England Journal of Medicine found that some of these weight loss drugs significantly reduce heart attacks, strokes, and cardiac deaths in obese patients with heart disease.
Although generally well tolerated, these medications can have side effects that some patients find distressing, such as nausea and bowel issues, leading some to discontinue treatment. Rare but serious side effects include eye, thyroid, and pancreatic problems. Another concern is the uncertainty regarding whether these medications need to be taken indefinitely, as some individuals regain weight after stopping therapy. The long-term risks, benefits, and complications of these drugs are still unknown and need further study in patients undergoing lifetime therapy.
The cost of these medications is also a significant issue, averaging around $1,000 per month, though prices vary based on drug company strategies and patient insurance. Experts predict that costs will decrease as more competitors, including pill forms, enter the market. Insurers might encourage Congress to cover these drugs as they recognize the savings from preventing heart disease and diabetes. While the high cost is a short-term strain on already overburdened healthcare budgets, it could reduce the need for surgical weight loss procedures and other medical interventions, potentially lowering expenses related to knee replacements, sleep apnea treatments, and food budgets.
Semaglutides and similar drugs offer a promising new approach to treating obesity, America's fastest-growing medical issue. There is still much to discover, and future treatments will likely see further improvements. Given the costs, potential complications, and other available options, these medications are unsuitable for everyone. As always, it is essential to consult with a healthcare professional to determine if these treatments are appropriate for you.
Today, obesity is more treatable than ever before. With various options available, patients no longer need to endure the health risks and stigmas of the past. However, caution is necessary. While diet and exercise might help you lose weight independently, committing to a long-term medication, whose long-term effects are still unknown, is a serious decision. It is not to be taken lightly.

IndraStra Global is now available on
Apple News, Google News, Feedly, Flipboard, and  WhatsApp Channel

COPYRIGHT: This article is published under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. https://creativecommons.org/licenses/by-nc-nd/4.0/

REPUBLISH: Republish our articles online or in print for free if you follow these guidelines. https://www.indrastra.com/p/republish-us.html